Taxane Compound Synthesis for Reduced Toxicity
Solution Overview
Problem
Existing taxane compounds exhibit high toxicity and low anti-tumor activity, particularly ineffective against leukemias and solid tumors such as gastrointestinal cancers, lung cancers, and breast cancers.
Innovation Solution
A new taxane compound with a specific structure, synthesized through a multi-step process involving protection and condensation reactions of gemcitabine and docetaxel, using specific reagents and conditions to achieve a compound with low toxicity and high anti-tumor activity.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing taxane compounds are used, then anti-tumor activity is achieved, but toxicity is high and anti-tumor activity is low
Solution Approach 1:
The patent modifies the chemical structure of taxane compounds by changing parameters such as introducing specific side chains (R1-R6) with defined lengths and compositions, modifying the C-13 substituent, and adjusting the C-25 substituent. These structural parameter changes result in compounds with improved anti-tumor activity and reduced toxicity compared to existing taxanes.
Solution Approach 2:
The patent creates composite molecular structures by combining multiple functional groups and substituents in a specific arrangement around the taxane core. The composite structure includes specific combinations of hydroxyl groups, alkyl chains, and functional moieties that work synergistically to enhance anti-tumor activity while reducing toxicity.
2Reliability
If existing taxane compounds are used, then some anti-tumor effect is achieved, but inhibitory effects on leukemias and solid tumors are poor
Solution Approach 1:
The patent designs taxane compounds with universal structural features that enable effective activity across multiple tumor types including leukemias and solid tumors. The specific substituent patterns (R1-R6) and core structure modifications create a multi-functional compound that can target various cancer cell types simultaneously, improving adaptability and versatility.
3Manufacturing precision
If multi-step synthesis process is used, then specific structure is achieved, but process complexity increases
Solution Approach 1:
The patent divides the complex synthesis process into discrete, manageable steps: protection of hydroxyl groups, formation of glycosidic bonds, introduction of side chains, and deprotection. Each step targets a specific structural element, allowing for precise control of the final molecule's structure while maintaining reasonable process complexity through systematic segmentation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new taxane compound demonstrates a maximum tolerated dose of 250 mg/kg and a tumor growth inhibition rate of up to 85.69% for colon cancer, showing significant efficacy against leukemias and solid tumors like lung and breast cancers with reduced toxicity.
Implementation Method 1
conducting a condensation reaction between the protected gemcitabine and alkyl chloroformate
Implementation Method 2
subjecting the intermediate D2 prepared by step S4 to hydroxyl deprotection
Data Source
Figure 1
Figure 2
Figure 3
AI summary
The present disclosure provides a new type of taxane compound and a preparation method and application thereof. The preparation method of the new type of taxane compound comprises the following steps: protecting two hydroxyl groups in gemcitabine, conducting a condensation reaction between the protected gemcitabine and alkyl chloroformate, and removing of hydroxyl protecting groups to obtain an intermediate G1; protecting a first hydroxyl group of the intermediate G1, and then protecting the other one of the hydroxyl groups, and removing a protecting group of the first hydroxyl group to obtain an intermediate G2; reacting 7,10-di-troc-docetaxel with dianhydride to obtain an intermediate D1; conducting a condensation reaction between the intermediate D1 and the intermediate G2 to obtain an intermediate D2; and subjecting the intermediate D2 to hydroxyl deprotection to obtain a target product. The new type of taxane compound of the present invention has low toxicity and high anti-tumor activity, and particularly has a good inhibition rate for leukemias and solid tumors such as gastrointestinal cancers, lung cancers, and breast cancers.